🔬 Current Disease Focus:
Task Progress: 0%
👥 Active Problem Solvers
0
🌍 Experts collaborating globally
⚡ Current Task Assignment
🧬 Genetic Analysis
🔄 Matching experts to specific tasks
📊 Resource Allocation by Research Phase:
📚 Data Analysis
🧪 Experimental Design
🔬 Clinical Trials
💊 Treatment Development
This study will evaluate the efficacy and safety of intravenous RC48-ADC co...
Status
Recruiting
Location
Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China
Start Date
2022-11-23
Trial ID
NCT05917158
Treatments Being Tested
This is an open-label, single-arm, Phase II investigator-initiated trial of...
Status
Unknown
Location
The First Bethune Hospital of Jilin University
Start Date
2021-11-01
Trial ID
NCT05115500
Treatments Being Tested
Objectives: To evaluate the non-inferiority of disitamab vedotin plus gemci...
Status
Recruiting
Location
The First Affiliated Hospital of Anhui Medical University
Start Date
2026-07-01
Trial ID
NCT07693959
Treatments Being Tested
This is a single-arm, open-label, Phase Ib/II clinical trial designed to ev...
Status
Not Yet Recruiting
Location
Sun Yat-sen University Cancer Center
Start Date
2025-04-30
Trial ID
NCT06957561
The purpose of this study is to evaluate the efficacy and safety of Disitam...
Status
Recruiting
Location
Fudan University Shanghai Cancer Center
Start Date
2023-11-28
Trial ID
NCT06178159
Treatments Being Tested
This study was a single-arm, open, multi-center Phase Ib/II clinical trial ...
Status
Recruiting
Location
Beijing Friendship Hospital
Start Date
2022-09-20
Trial ID
NCT05403242
This is an open-label, single-arm, Phase Ib/II investigator-initiated trial...
Status
Unknown
Location
Beijing Cancer Hospital
Start Date
2020-02-15
Trial ID
NCT04264936
Treatments Being Tested
This study is being done to see if a drug called disitamab vedotin, alone o...
Status
Recruiting
Location
Banner Gateway Medical Center
Start Date
2022-05-03
Trial ID
NCT04879329
Treatments Being Tested
This study will evaluate the efficacy and safety of RC48-ADC combined with ...
Status
Unknown
Location
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Start Date
2023-08-03
Trial ID
NCT06178601
In this study, 60 patients with HER2 overexpression UTUC with high-risk rec...
Status
Recruiting
Location
Peking University First Hospital
Start Date
2024-02-20
Trial ID
NCT06210490
Treatments Being Tested